It is widely reported that inflammatory mediators are involved in MS pathogenesis, in order to assess whether our compounds could modulate inflammatory pathways, we analyzed in MS patients and healthy donors, the expression of Akt, a relevant protein of the phosphatidylinositol 3′ –kinase (PI3K)-Akt signaling pathway. The gene discussed is AKT1; the disease is myeloid sarcoma.